The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.
McCarthy EM, Sutton E, Nesbit S, Parker B, Jayne D, Griffiths B, Isenberg DA, Rahman A, Gordon C, D'Cruz DP, Rhodes B, Lanyon P, Vital EM, Yee CS, Edwards CJ, Teh LS, Akil M, McHugh NJ, Zoma A, Bruce IN; British Isles Lupus Assessment Group Biologics Register.
McCarthy EM, et al. Among authors: vital em.
Rheumatology (Oxford). 2017 Jun 1;56(6):1041-1043. doi: 10.1093/rheumatology/kex044.
Rheumatology (Oxford). 2017.
PMID: 28431104
Free PMC article.
No abstract available.